Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Shares Outstanding (Diluted Average): 2022-2025

Historic Shares Outstanding (Diluted Average) for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $41.5 million.

  • Entrada Therapeutics' Shares Outstanding (Diluted Average) rose 2.05% to $41.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.5 million, marking a year-over-year increase of 2.05%. This contributed to the annual value of $39.0 million for FY2024, which is 18.01% up from last year.
  • As of Q3 2025, Entrada Therapeutics' Shares Outstanding (Diluted Average) stood at $41.5 million, which was up 0.30% from $41.3 million recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Shares Outstanding (Diluted Average) peaked at $41.5 million during Q3 2025, and registered a low of $31.2 million during Q1 2022.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $35.5 million (2024), whereas its average is $37.0 million.
  • Data for Entrada Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY rose of 18.06% (in 2025) over the last 5 years.
  • Over the past 4 years, Entrada Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $31.3 million in 2022, then climbed by 5.61% to $33.1 million in 2023, then increased by 18.01% to $39.0 million in 2024, then climbed by 2.05% to $41.5 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $41.5 million in Q3 2025, compared to $41.3 million in Q2 2025 and $41.1 million in Q1 2025.